177 related articles for article (PubMed ID: 38275065)
1. Therapeutic Chemoresistance in Ovarian Cancer: Emerging Hallmarks, Signaling Mechanisms and Alternative Pathways.
Zaib S; Javed H; Rana N; Zaib Z; Iqbal S; Khan I
Curr Med Chem; 2024 Jan; ():. PubMed ID: 38275065
[TBL] [Abstract][Full Text] [Related]
2. New Achievements from Molecular Biology and Treatment Options for Refractory/Relapsed Ovarian Cancer-A Systematic Review.
Bachmann C
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001616
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
4. Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors.
Alam S; Giri PK
Cancer Drug Resist; 2024; 7():6. PubMed ID: 38434767
[TBL] [Abstract][Full Text] [Related]
5. Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.
Cornelison R; Llaneza DC; Landen CN
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29057791
[TBL] [Abstract][Full Text] [Related]
6. Chemoresistance in Ovarian Cancer: Prospects for New Drugs.
Tendulkar S; Dodamani S
Anticancer Agents Med Chem; 2021; 21(6):668-678. PubMed ID: 32900355
[TBL] [Abstract][Full Text] [Related]
7. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer.
Lukanović D; Herzog M; Kobal B; Černe K
Biomed Pharmacother; 2020 Sep; 129():110401. PubMed ID: 32570116
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer resistance to PARPi and platinum-containing chemotherapy.
Summey R; Uyar D
Cancer Drug Resist; 2022; 5(3):637-646. PubMed ID: 36176755
[TBL] [Abstract][Full Text] [Related]
9. Current Advances and Outlook in Gastric Cancer Chemoresistance: A Review.
Zhang SX; Liu W; Ai B; Sun LL; Chen ZS; Lin LZ
Recent Pat Anticancer Drug Discov; 2022; 17(1):26-41. PubMed ID: 34587888
[TBL] [Abstract][Full Text] [Related]
10. Glutathione Transferase P1: Potential Therapeutic Target in Ovarian Cancer.
Simic P; Pljesa I; Nejkovic L; Jerotic D; Coric V; Stulic J; Kokosar N; Popov D; Savic-Radojevic A; Pazin V; Pljesa-Ercegovac M
Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36422199
[TBL] [Abstract][Full Text] [Related]
11. Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer.
Zamwar UM; Anjankar AP
Cureus; 2022 Oct; 14(10):e30561. PubMed ID: 36415372
[TBL] [Abstract][Full Text] [Related]
12. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer.
Li M; Balch C; Montgomery JS; Jeong M; Chung JH; Yan P; Huang TH; Kim S; Nephew KP
BMC Med Genomics; 2009 Jun; 2():34. PubMed ID: 19505326
[TBL] [Abstract][Full Text] [Related]
13. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
14. The effects of REG4 expression on chemoresistance of ovarian cancer.
Xiang LW; Xue H; Ha MW; Yu DY; Xiao LJ; Zheng HC
J Obstet Gynaecol; 2022 Oct; 42(7):3149-3157. PubMed ID: 35929918
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets.
Alatise KL; Gardner S; Alexander-Bryant A
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551731
[TBL] [Abstract][Full Text] [Related]
16. Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine.
Guo C; Song C; Zhang J; Gao Y; Qi Y; Zhao Z; Yuan C
Genes Dis; 2022 May; 9(3):668-681. PubMed ID: 35782973
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review.
Binju M; Padilla MA; Singomat T; Kaur P; Suryo Rahmanto Y; Cohen PA; Yu Y
Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):371-378. PubMed ID: 30423357
[TBL] [Abstract][Full Text] [Related]
18. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract][Full Text] [Related]
19. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.
Vecchione A; Belletti B; Lovat F; Volinia S; Chiappetta G; Giglio S; Sonego M; Cirombella R; Onesti EC; Pellegrini P; Califano D; Pignata S; Losito S; Canzonieri V; Sorio R; Alder H; Wernicke D; Stoppacciaro A; Baldassarre G; Croce CM
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9845-50. PubMed ID: 23697367
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Sensitization of High-Grade Serous Ovarian Cancer Cells Lacking Caspase-8 Expression to Chemotherapeutics Using Combinations of Small-Molecule BRD4 and CDK9 Inhibitors.
Gasimli K; Raab M; Mandal R; Krämer A; Peña-Llopis S; Tahmasbi Rad M; Becker S; Strebhardt K; Sanhaji M
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
